Elanco (NYSE: ELAN) details investor presentation for J.P. Morgan event

Rhea-AI Filing Summary

Elanco Animal Health Incorporated filed a report stating that on January 13, 2026, it will present at the 44th Annual J.P. Morgan Healthcare Conference. The company has prepared an investor presentation for this event, which is included as Exhibit 99.1. This presentation is being made available as supplemental information for investors and analysts.

The disclosure is furnished under a provision that means it is not considered “filed” for liability purposes under the Securities Exchange Act and will only be incorporated into other documents if expressly stated. No financial results, transactions, or strategic changes are described in this report beyond the announcement of the conference presentation.

false 0001739104 Elanco Animal Health Incorporated 0001739104 2026-01-12 2026-01-12 0001739104 us-gaap:CommonStockMember 2026-01-12 2026-01-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): January 12, 2026

Elanco Animal Health Incorporated

(Exact name of registrant as specified in its charter)

Indiana		001-38661		82-5497352
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

450 Elanco Circle Indianapolis, Indiana (Address of principal executive offices) 46222 (Zip Code)

Registrant’s telephone number, including area code: (877) 352-6261

Not Applicable

(Former Name or Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, no par value		ELAN		New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

¨  Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 7.01 Regulation FD.

On January 13, 2026, Elanco Animal Health Incorporated (the “Company”) will present at the 44th Annual J.P. Morgan Healthcare Conference (the “JPM Conference”). A copy of the Company’s JPM Conference presentation is furnished as Exhibit 99.1.

The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Investor Presentation of Elanco Animal Health Incorporated at the JPM Conference.
104.1		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Elanco Animal Health Incorporated
Date: January 12, 2026	By:	/s/ Robert M. VanHimbergen
		Name: Robert M. VanHimbergen
		Title: Executive Vice President, Chief Financial Officer

FAQ

What did Elanco Animal Health (ELAN) disclose in this 8-K?

Elanco Animal Health disclosed that it will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, and furnished its investor presentation as Exhibit 99.1.

When is Elanco Animal Health presenting at the J.P. Morgan Healthcare Conference?

Elanco Animal Health is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026.

What is included as Exhibit 99.1 in Elanco Animal Health's 8-K?

Exhibit 99.1 is the investor presentation of Elanco Animal Health Incorporated that will be used at the J.P. Morgan Healthcare Conference.

Is Elanco Animal Health's investor presentation considered filed with the SEC?

The investor presentation in Item 7.01, including Exhibit 99.1, is being furnished and is not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934.

Can Elanco’s J.P. Morgan conference presentation be incorporated into other SEC documents?

The presentation will not be incorporated by reference into other registration statements or documents under the Securities Act or Exchange Act, except if expressly stated in a future filing.

Who signed Elanco Animal Health's 8-K related to the J.P. Morgan conference?

The report was signed on behalf of Elanco Animal Health Incorporated by Robert M. VanHimbergen, Executive Vice President and Chief Financial Officer.